advertisement

HIV/AIDS

14 July 2011

More proof that PrEP works

There is growing evidence that a daily dose of antiretroviral treatment taken by the HIV-negative partner in HIV-discordant relationship can reduce the risk of HIV transmission.

A new study has added to growing evidence that a daily dose of antiretroviral treatment taken by the HIV-negative partner in a heterosexual, HIV-discordant relationship can significantly reduce the risk of HIV transmission.

The Partners PrEP trial, the largest to date to consider the effectiveness of pre-exposure prophylaxis (PrEP) for HIV prevention, involved 4,758 HIV-negative people in Kenya and Uganda, all with HIV-positive partners. One-third of HIV-negative participants took a daily tablet of the antiretroviral, tenofovir; one-third a combination of tenofovir and emtricitabine; and the rest a placebo. The trial, begun in July 2008 and conducted by the University of Washington's International Clinical Research Centre, ended a year early due to the overwhelming evidence produced.

Second study

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.